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Available online 10 June 2016The health risks associated with electronic cigarettes (ECs) are largely unknown. The purpose of this systematic
review was to evaluate published case reports that deal with health effects attributed to EC use. An Internet
searchwas conducted to identify case reports dealingwith the effects of ECuse onhealth. Twenty-six case reports
representing 27 individuals (one study contained reports for two individuals) were published between April
2012 and January 2016, and these were grouped into categories of effect according to their health outcomes.
Of the 27 individuals, 25 had negative effects subsequent to use or exposure to ECs and their reﬁll ﬂuids, while
two reported improvement in chronic immune and gastrointestinal conditions. Three categories of negative
health effects were identiﬁed: systemic effects, nicotine poisoning, and mechanical injury. Thirteen cases reported
EC effects on different systems including: respiratory (6), gastrointestinal or developing intestine of an infant (3),
cardiovascular (2), neurological (1), and immune (1). Twelve cases involved nicotine poisoning resulting from
accidental (N=3),misuse/abuse (N=1), or suicidal/intentional ingestion (N=8); four of these involved children
and three resulted in adult fatalities. Two cases reportedmechanical injury caused by an EC battery explosion. Most
case reports show that the health of children and adults can be negatively affected by EC products and that if death
does not occur, negative effects can be reversed. Data further indicate that EC use can cause negative health effects in
previously healthy individuals and exacerbate pre-existing conditions.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Electronic cigarettes (ECs) are battery-operated devices that heat a
liquid containing propylene glycol and/or glycerin, nicotine, and
ﬂavorings to produce an aerosol which users inhale (Trtchounian and
Talbot, 2011; Grana et al., 2014). In spite of their rapid rise in popularity
and worldwide sales, the effects of EC use on short and long-term
human health are poorly understood. Because EC aerosol contains fewer
chemicals than conventional tobacco smoke, EC are often considered a
safe alternative to cigarettes. However, EC are not without health risks.
Information linking EC use to health effects has been gained mainly
from short-term in vitro studies with cultured cells and in vivo experi-
ments with human subjects (Pisinger and Døssing, 2014). In vitro studies
have shown that cytotoxic effects vary among EC reﬁll ﬂuids (Bahl et al.,
2012), some ﬂavor chemicals (such as cinnamaldehyde) have toxicity at
the concentrations used in EC (Behar et al., 2014a,b; Lerner et al., 2015),
and stem cells are more sensitive than differentiated adult lung cells to
EC products (Bahl et al., 2012; Behar et al., 2014a). Recent studies have
further shown that EC aerosols induced DNA strand breaks and reduced
cell survival in vitro (Yu et al., 2016). EC aerosols also reduced endothelial
barrier function in cultured lung microvascular endothelial cells and in-
creased inﬂammation and oxidative stress in mice (Schweitzer et al.,
2015; Sussan et al., 2015).Most in vivo studies have involved experiments
with human subjects, and these were recently reviewed (Pisinger and
Døssing, 2014). An infodemiological study of online forums found405dif-
ferent health-related effects (78 positive, 326 negative, 1 neutral) attrib-
uted by users to EC (Hua et al., 2013). Of recent concern is the ﬁnding
that a high percentage of EC reﬁll ﬂuids contain toxicants such as diacetyl
anddiethylene glycol (Westenberger, 2009; Varlet et al., 2015; Allen et al.,
2015), and EC aerosols contain formaldehyde-hemiacetals, ultraﬁne par-
ticles, and metals (Jensen et al., 2015; Williams et al., 2013, 2015). The
EC industry is making hundreds of new EC models and thousands of
ﬂavors of e-liquids or reﬁll ﬂuids available to consumers (Zhu et al.,
2014; Tierney et al., 2015). Althoughmany of theseﬂavors are considered
safe for ingestion by the Flavor Extracts Manufacturers Association
(FEMA), their inhalation safety has not been established by FEMA
(Hallagan, 2015).
Additional information on EC health effects can be gained from case
reports on EC users who present to physicians with symptoms attributed
to EC use or exposure. The number of case reports that appears in the
peer-reviewed literature has reached a critical mass and is currently
worth mining to gain further insight into the positive and negative
health effects appearing in EC users. The purpose of this study was to
systemically collate and analyze the existing case reports linking EC
use to health outcomes and to identify categories of health effects related
to EC use.
2. Methods
This review follows the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-analysis) guidelines for conducting
systematic reviews. The ﬂowchart for the systematic review is repre-
sented in Fig. 1.
2.1. Search strategy
An Internet search using the keywords or phrases: “electronic
cigarette”, “e-cigarette case reports”, “e-cigarette case studies”, and
“e-cigarette nicotine poisoning case reports” was carried out in
PUBMED, MEDLINE, and general internet search engines. Additionalsearches with the keywords followed by year were used (i.e. “e-cigarette
case report 2012”). References in case reports or other related peer-
reviewed literature also contributed to gathering literature.
2.2. Inclusion criteria
Case reports and reviewed abstracts dealing with health effects
attributed to EC use or exposure were included. At a minimum, the
cases reporting systemic effects needed to: (1) clearly discuss the
patient's symptoms upon presentation and (2) be reported and diag-
nosed by healthcare professionals.
Similarly, cases reporting nicotine poisonings or mechanical injuries
needed to provide information concerning the context of EC use and/or
summarize health impacts on the patient documented by a healthcare
professional.
2.3. Exclusion criteria
Case reports or abstracts that reported on EC use or EC products
without direct correlation to health effects were excluded from the
study. Reports that dealt with health effects caused by liquid nicotine
unassociated with EC were not included.
2.4. Identiﬁcation and selection of case reports
The search strategy identiﬁed 49 articles that attributed health
effects to EC use or EC products. Twenty-two of these consisted of orig-
inal case reports and abstracts that matched search criteria for articles
dealing with health effects attributed to EC use or exposure. Nineteen
were in the peer-reviewed literature and ﬁve were reviewed abstracts
(one of these presented two individual cases). The authors agreed on
the inclusion criteria for case reports and reviewed conference abstracts
that contained sufﬁcient details on health effects related to EC for inclu-
sion in the Results section. The general search yielded 27 articles and
news reports that were not included in the evaluation; however, ﬁve of
these which relate to death and serious illness as well as two regarding
perception of EC use during pregnancy are included in the Discussion sec-
tion. In addition, examination of reference lists in case reports and articles
(Ruokolainen et al., 2015; Kim and Baum, 2015) that cited case reports
yielded four reports for inclusion (Eberlein et al., 2014; Schipper et al.,
2014; Bartschat et al., 2015; Gupta et al., 2014). These literature refer-
ences also yielded one additional case that reported that adverse health
effects associated with liquid nicotine not found in the online search
(Kivrak et al., 2014). This case was conﬁrmed to be linked to EC use by
correspondence with the original authors (Kivrak et al., 2014).
3. Results
3.1. Overview of case reports
Of 26 case reports for 27 individuals identiﬁed in the Internet search,
25 individuals experienced negative health effects and 2 reportedpositive
or improved outcomes attributed to EC usage (Table 1). The case reports
came from 10 countries and included pediatric and adult populations
ranging in age from newborn (1 day old) to 70 years old. Most users
who experienced health effects were adults (male N= 15; female N=
7) and ﬁve were children. A few case reports dealt with EC users who
were former smokers (N = 3) or quit smoking for one month or more
(N=3). Three deathswere associatedwith ECuse. The case report cohort
included 13 individuals with pre-existing health conditions (eight
Fig. 1. Flowchart of the procedure used to collect case reports that are included in the systematic review.
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experienced negative health effects. Four experienced health effects
related to worsening of a preexisting condition.
Four of six patients who used EC for smoking cessation experienced
negative effects. Of these, three patients were dual users of EC and ciga-
rettes, and two experienced negative effects, while one had positive
effects.
Three categories of health effects attributed to EC use could be iden-
tiﬁed in the case reports and abstracts. Systemic health effects (N=13)
were associated with conditions relating to body systems/organs.
Nicotine poisonings (N=12)were associated with ingestion or internal-
ization of liquid nicotine, and varying symptoms of nicotine poisoning
were reported for adults and pediatrics. Mechanical injury (N = 2)
included adverse effects resulting from EC explosions. The median age
for systemic events was 42. For nicotine poisonings the median age was
23. The patients injured by mechanical explosion were both male, aged
18 and 30. All reviewed case reports indicated no conﬂicts of interest;
for reviewed abstracts, no statements on conﬂicts of interest were
given. Each of these categories will be discussed in order of reporting
prevalence.
3.1.1. Respiratory system
Six case reports involved the respiratory system. The speciﬁc
diagnoses were two cases of exogenous lipoid pneumonia
(McCauley et al., 2012; Modi et al., 2015), and one case of each of
the following: bronchiolitis (Hureaux et al., 2014), acute eosinophil-
ic pneumonia (Thota and Latham, 2014), pneumonia with bilateral
pleural effusions (Moore et al., 2015), and inhalation injury and suspected
acute hypersensitivity pneumonitis (Atkins and Drescher, 2015). The pa-
tient who experienced acute eosinophilic pneumonia was described aspreviously healthy. Onepatientwith lipoid pneumonia had adverse respi-
ratory health effects that coincided with 7 months of EC use. The patient
with bronchiolitis had previously been treated for pulmonary adenocarci-
noma, and the patient with pneumonia with bilateral pleural effusions
had a history of hypertension.
Upon presentation, the patients with negative effects were experienc-
ing symptoms such as shortness of breath and cough. Although each
diagnosis was different for ﬁve of six patients, the six patients with nega-
tive effects were all diagnosed with inﬂammation of the respiratory
system. For the individuals with bronchiolitis, acute eosinophilic pneu-
monia, and pneumonia with bilateral pleural effusions, the onset of
symptoms occurred within 3 days–7 days of EC use. In the two cases
of lipoid pneumonia, the patients experienced an onset of respiratory
symptoms 7 months and 3 months after starting EC use. The patient
who experienced inhalation injury and suspected acute hypersensitivity
pneumonitis had a history of previous medical admittance related
to respiratory concerns and he had used EC before his prior medical
admittance.
Four of the patients' conditions improved and they had no further
symptoms after seeking medical care and abstaining from EC use. The
conditions of the two patients diagnosed with acute eosinophilic pneu-
monia and pneumonia with bilateral pleural effusions also improved,
however, it was not reported if they abstained from EC use in addition
to their medical treatment.
Details concerning reﬁll ﬂuid ﬂavors were provided in two of the six
respiratory cases. The patient diagnosed with bronchiolitis was using
twodifferent brands of EC liquidswith tobaccoﬂavoring that had nicotine
concentrations of 19 mg/ml, while the patient suffering from inhalation
injury and suspected acute hypersensitivity pneumonitis used tobacco
and an unspeciﬁed “sweet ﬂavoring containing diacetyl”.
Table 1
Case reports involving EC health effects.
Patient Demographics Pre-existing (1) Smoking History (1) Presentation/Signs (1) Treatment Other Notes &
(Age, Sex, Country) Medical History (2) EC Device/ Refill Fluid Info (2) Diagnosis (2) Health Outcome Comments
SYSTEMIC EFFECTS 
RESPIRATORY
McCauley et al (2012)
42, F, USA 7 month history dyspnea, produc- (1) N/A (1) 7 month history of dyspnea, (1) Abstained EC use; First respiratory case 
tive cough, subjective fevers, (2) No EC brand, EC refill fluid  productive cough, subjective prescribed medication report attributed to EC
asthma, rheumatoid arthritis, specified. 7 month history of EC fever. Mild tachycardia (2) Symptoms improved after use. Three other 
fibromyalgia, schizoaffective dis- use. (2) Exogenous lipoid pneu- abstained EC use; chest radio- known cases of lipoid
order, hypertension. Respiratory monia due to EC use. graph showed mild diffusion pneumonia linked to
symptoms coincided with EC use impairment but no permanent EC have been  
7 months prior. damage. reported. 
Hureaux et al. (2013) 
43, M, FR Pulmonary lung adenocarci- (1) 45 pack-yr., history; cessation (1) Bronchial syndrome (1) Abstained EC use 
noma and isolated brain meta- attempt with 21 mg nicotine patch associated with deterioration (2) After 48 hr. improvement
stasis. and cont. smoking 20 cig/day. of pulmonary function tests in cough, sputum, breathless- 
(2) La dynamique (CIGARTEX);  after starting EC use. ness; by day 7 all symptoms
EC refill fluids: Kentucky and (2) Subacute bronchial toxicity resolved. 
Eastern (19 mg/ml). Vaped 25x/
day, 5-6 puffs/session 
(125-150/day).
Thota et al. (2013) 
20, M, USA Previously healthy; (1) N/A (1) Shortness of breath, (1) Prescribed medications Trigger undesired 
Family history of pulmonary (2) No EC brand, EC refill fluid tachycardia. (2) Resolved health effects after respiratory effects in 
embolism specified. (2) Acute eosinophilic pneumonia receiving medical care and previously healthy
treatment. individual.
Moore et al. (2015) 
43, M, US History of hypertension. (1) Unspecified 7 yr. smoking (1) Shortness of breath, pleuritic (1) Breathing treatments and Fourth case of 
history. chest pain. . antibiotic treatments. pneumonia and 
(2) No EC brand, EC refill fluid (2) Pneumonia and bilateral  (2) Dismissed after two days first case of pleurisy 
specified. pleural effusions. hospitalization and resolved.
Atkins and Drescher (2015)
60, M, USA N/A. (1) Unspecified smoking history (1) Weakness, chills, cough (1) Medical care received Inhalation of EC refill
(2) No EC brand, EC refill fluid (2) Inhalation injury and   (2) Symptoms improved after fluids with diacetyl can  
specified, suspected hypersensitivity abstained EC use; prescribed be a potential health
medication concern.
Modi et al. (2015)
31, F, USA N/A (1) Unspecified smoking history (1) Progressive dyspnea, cough (1) Medical carereceived  Second case report of 
(2) No EC brand, EC refill fluid (2) Acute lipoid pneumonia (2) Symptoms improved after  lipoid pneumonia 
specified. abstained EC use; prescribed reported in USA.
medication.
GASTROINTESTINAL
Lee et al. (2013) 
35, M, USA 1.5 yr. history of pan-ulcerative (1) Past smoker; details not (1) Before EC use: daily bloody (1) EC use initiated. EC use with smoking
colitis (UC); began4 weeks after provided. bowel movements with severe (2) EC use was associated with cessation helped
smoking cessation. (2) No EC brand, EC refill fluid  incontinence. steroid-free clinical remission symptoms.
specified mean 105 puffs/day (2) Relapsed medically refractive in patient UC.
(range: 45-191). UC after EC use. 
.
Camus et al. (2014)
49, F, FR UC affecting rectum and (1) 20 cigarettes/day for 20 yrs. (1) UC symptoms began 3 (1) Patient resumed smoking 9 Indicates nicotine 
rectum and sigmoid colon diag- (2) No EC brand info; 30 mg liq- months after patient quit smoking; months after UC diagnosis may not be the only
nosed in 2004; Hysterectomy uid nicotine/day  with use of dis- bloody diarrhea. (2) Clinical remission within a factor with protective
for endometriosis diagnosed in posable cartridges of 10 ml every 2) Smoking dependent UC few days of resumed cigarette effects for UC.
2008 5 days containing 16 mg/ml smoking.
nicotine.
Gillen and Saltzman (2014) 
1 day old infant, M, USA Gastrointestinal bleeding (1) N/A (1) Abdominal distention, res- (1) Double barrel ileostomy with First pregnancy
(2) N/A; suspected cause due to piratory distress. subsequent surgery procedures health effect linked 
in utero exposure, mother using (2) Isolated chronic necrotizing (2) At 6 months infant recovered; to EC use.
EC ~30-50 x/day; ~50-70 x/day. enterocolitis. 9 month development milestone 
No EC brand, EC refill fluid met.
specified.
CARDIOVASCULAR
Monroy et al. (2013)
70, F, USA Hypertension, hyperlipidemia (1) 40 pack-yr. history; attempt (1) Subsequent hematoma (1) Patient asked to discon- Although the patient
osteoarthritis, allergic rhinitis, -ed cessation in preceding 5-6 drainage, patient developed 3 tinue EC use. has significant med-
remote history of breast adeno- months. ep. of asymptomatic acute  (2) Eliminated episodes of AF ical history, all AF
carcinoma; right hip fracture. (2) No EC brand, EC refill fluid atrial fibrillation (AF). for remainder of hospitalization episodes occurred
specified (2) Paroxysmal AF only during EC use.
Kivrak et al. (2014)
24, M, TR Previously healthy (1) 1 pack/day for 4 yrs.; 1 month (1) Chest pain 4 hrs. prior to EC (1) Prescribed medication Myocardial infarction
cessation attempt. refill fluid use. (2) Evaluated one month later in individuals <30 yr.
(2) No EC brand specified;  (2) Acute myocardial infarction and free of symptoms. of age is rare.
tobacco flavored nicotine con-
centration 16 mg/day use.
NEUROLOGICAL
Vannier et al. (2015)
39, M, FR Previously healthy (1) 60 cig/day for 20 yrs. (1) 7 day history of headaches (1) Prescribed med and  First neurological 
(2) No EC brand specified; and 2 seizures. abstained EC use; continued negative case report
Nicotine concentration was (2) Reversible cerebral vaso- smoking 10-15 cig/day with associated with EC
12 mg/ml. constriction syndrome. nicotine patch. use.
(2) Headache resolved by day 
3, no recurrence of seizures.
IMMUNE
Farsalinos et al. (2013)
28, M, GR       Chronic idiopathic neutrophilia (1) Smoker since 1996; 9 pack-yr (1) After EC use, patient quit (1) Prescribed medication for First positive health
(CIN) since 2005; hyperlipidemia  (2) No EC brand specified; smoking in 10 days and leuko- elevated LDL levels, cont. EC use effected attributed to
treated with medication; no other nicotine concentration 9 mg/ml cyte and C reactive protein (2) Smoking cessation with EC EC use in case re-
History of infection/trauma, fever. normalized in 6 months. use reversed CIN. port literature.
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Table 1 (continued)
NICOTINE POISONINGS 
ACCIDENTAL POISONINGS
Bassett et al. (2014)
10 month old infant, M, USA N/A (1) N/A (1) Vomiting, tachycardia (1) Unspecified medical First reported case
(2) N/A; affected accidental ingestion of grunting respirations, truncal treatment. of nicotine poisoning
Wintergreen EC refill fluid with nicotine  ataxia developed after (2) Recovered baseline in a young child in
(18 mg/mL) but unknown PG, glycerin, ingestion of EC refill fluid. health after 6 hrs. of literature.
and flavoring concentrations. (2) Nicotine poisonings ingesting EC refill fluid.
Gupta et al. (2014)
30 month old child, F, UK N/A (1) N/A (1) Vomiting (1) No treatment; observed to Nicotine poisonings 
(2) N/A; affected by accidental ingestion of (2) Nicotine poisoning be systemically well. for children increase
EC refill fluid. No EC brand or further details (2) Resolved without intervention. and reported inter-.
on EC refill fluid were provided. nationally.
Gill et al. (2015)
2, F, CN N/A (1) N/A (1) Sudden onset vomiting and (1) No treatment; observed to  See above.
(2) N/A; affected by accidental ingestion of Irritability resolving at time of pre- be at patient baseline for 2 hr. 
EC refill fluid. No EC brand, EC refill fluid sentation. before discharge. 
specified. One 60 ml bottle 24 mg/mL of (2) Nicotine poisoning; potential (2) Resolved without intervention
grape flavored EC refill fluid suspected. mild toxicity effects. 
POISONINGS CAUSED BY INTENTIONAL MISUSE AND/OR ABUSE OF EC
Cervellin et al. (2013)
22, F, IT N/A (1) N/A for smoking. Patient has opiod (1) Tachycardia, flushing, saliva- (1) Unspecified medical treat- EC abuse with other 
addiction. tion, and nausea. ment if any. Patient observed  drugs. 
(2) No EC brand, EC refill fluid specified. (2) Nicotine poisoning by inten- and discharged after psychiatric  
Mixed residual content of EC fluid (10 ml tional ingestion and abuse of counseling and directed to  
of 0.8% solution)  with 60 ml of methadone. nicotine/drugs. addiction services.
Injected 2 ml of solution; ingested 60 ml (2) No follow-up details.
was reported.
SUICIDE ATTEMPTS
*Christensen et al. (2013)
(a) 36, F, DK N/A (1) N/A (1) No symptoms (1) Admitted to emergency ward; Patient tried to 
(2) No EC brand specified. Ingested 20 ml (2) N/A treated with activated charcoal. commit suicide twice
EC refill fluid containing 18 mg nicotine. (2) No follow-up details. using EC refill fluid.
(b) Same as above N/A (1) N/A (1) Two hrs. after ingestion (1) Treated with activated char-
(2) No EC brand specified. Ingested 50 ml abdominal pain, nausea, vomiting coal and 6 hr. observation.
EC refill fluid containing 30 mg nicotine. (2) Nicotine poisoning by inten- (2) No follow-up details.
tional ingestion.
Christensen et al. (2013) 
13, M, DK N/A (1) N/A (1) Nausea and shivering (1) Activated charcoal treatment Easily available to
(2) No EC brand specified. Ingested 3 mL of (2) Nicotine poisoning by inten- (2) No follow-up details younger population;
EC refill fluid, but no details on concentration tional ingestion; mild toxicity . Potentially less dose
needed to induce 
toxic effects.
Eberlin et al. (2014)
24, M, DE Depressive and sex- (1) N/A (1) 10 minutes after ingestion (1) Activated charcoal treatment. Suicide attempt
ual identity disorders. (2) Ingested one capsule of nicotine liquid patient vomited. Nausea per- (2) Symptoms cleared, unspeci-
used in EC containing 180 mg nicotine. sisted for a few hrs. Dizziness. fied.
(2) Nicotine poisoning by inten-
tional ingestion.
Valento (2013)
22, M, USA N/A (1) N/A (1) Dizziness, nausea, mild tremor (1) Skin decontamination Nicotine poison
(2) No EC brand specified. and brachycardia. Ingested 30 ml  prior to ER visit; unspecified health effects may 
EC liquid nicotine (24 mg/ml). medical treatment.
Rubbed additional 30 ml dermally. (2) Complete recovery
(2) Nicotine poisoning by inten-
tional ingestion.
Thornton et al. (2014)
29, M, USA History of depression (1) Previous smoker; history unspecified (1) Cardiovascular resuscitation; (1) N/A First suicide report 
(2) N/A; No EC brand, EC refill fluid   full body seizure (2) Death by intravenous injection. by using EC refill 
specified. Fatal intravenous injection using (2) Death caused by intentional fluid.
EC refill fluid. intravenous injection of EC
refill fluid.
Declared brain dead day 5.
Schipper et al. (2014)
27, M, NL Borderline personality (1) N/A (1) Before ER arrival, patient (1) Activated charcoal (3x); Individuals with  
disorder (2) N/A; No EC brand specified. Ingested vomited 3 times but no com- 24 hr. observation period. mental illness may
5 EC fillings with nicotine (420 mg total). plaints upon ER arrival. (2) Discharged after 30 hr. ob- be vulnerable to
(2) Nicotine poisoning by inten- servational period with no ad- intentional poisoning
tional ingestion. verse events and psychiatric and self-harm by
consultation. misuse of EC.
Bartschat et al. (2015)
34, M, DE Psychosis (1) N/A (1) Medical autopsy revealed fa- (1) N/A Same as above
(2) N/A; No EC brand specified. Suspected tal and significant nicotine con- (2) Death
72 mg/ml. Mother of victim also centrations in femoral blood, 
found 5 nicotine solution “Titanium Ice” vials, (5.5 mg/L) lungs (89.5 mg/kg)  
3 of which were empty. and in kidney tissue (42.6 mg/kg)
(2) Fatal EC refill fluid ingestion.
Chen et al. (2015)
24, F, USA Unspecified mental (1) N/A (1) Medical autopsy revealed (1) N/A Same as above
disorder/psychiatric (2) N/A; No EC brand specified. Found  significant plasma and nicotine (2) Death; multiple acute infarcts;
15 ml vials (100 mg/ml) of EC liquid nicotine. Concentrations over 1000 ng/mL severe anoxic brain injury. Died 
(2) Fatal EC refill fluid ingestion. 3 days post-ingestion.
:
MECHANICAL INJURIES
Jablow et al. (2015)
30, M, USA Previously healthy (1) N/A (1) Partial thickness burns to (1) Treatment with intravenous First burn case 
(2) N/A; No EC brand specified. right leg and knee. opioid analgesia. Burn wounds report attributed
(2) Mechanical injury caused treated and patient was trans- to EC explosion.
by spontaneous explosion of ported to closest burn center.
EC battery. (2) No follow-up specified.
Rogér et al. (2016)
18, M, USA Attention-deficit/ (1) N/A (1) Oral trauma; tooth avulsion (1) Treatment at burn center Second mechanical 
hyperactivity disorder (2) N/A; No EC brand specified. and severe mouth burns (2) Follow up dental recon- injury case; first oral 
(ADHD) (2) Mechanical injury caused struction. trauma.
by spontaneous explosion of 
EC battery.
* = three cases reported in one case report. One case was a follow-up to a second poisoning attempt by the patient.
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bronchiolitis used his EC 25–26 times per day, and in each session,
he reported taking approximately 5–6 puffs. In addition to EC use, this
patient smoked 20 cigarettes a day. The patient diagnosedwith pneumo-
nia with bilateral pleural effusions estimated that he puffed hundreds of
times/day for 3 days.
3.1.2. Gastrointestinal system
Three case reports involved the gastrointestinal system. The speciﬁc
diagnoses were relapsed ulcerative colitis (UC) (Camus et al., 2014),
clinical remission of UC (Lee et al., 2013), and necrotizing enterocolitis
in the developing gut of an infant (Gillen and Saltzman, 2014). Both
adult patients (amale and female) had a history of UC andwere previous
smokers.
Upon presentation, the patients with negative effects experienced
different gastrointestinal symptoms. The patient with relapsed UC
experienced bloody diarrhea. The infant who had necrotizing enterocoli-
tis experienced intestinal bleeding. The patient with clinical remission of
UC had experienced bloody bowel movements with severe incontinence
before EC usage.
For the individuals with relapsed UC and remission of UC, the onset
of symptoms occurred 3 months after the patient quit smoking and
4 weeks after smoking cessation and initiation of EC use, respectively.
In the case of the infant with necrotizing enterocolitis whowas exposed
to EC in utero, symptoms began shortly after birth.
The patient with relapsed UC experienced improvement in her
condition after she stopped EC use and resumed smoking. The infant
experiencing necrotizing enterocolitis required multiple surgeries, but
follow-up reports indicated he recovered and developed normally
after the surgeries. The patient who experienced UC remission after EC
use continued EC usage and smoking cessation. However, there was
no additional follow-up on this patient. The patient who experienced
relapsed UC was using both EC reﬁll ﬂuid with 30 mg of nicotine/ml
daily and a cartridge with 16 mg of nicotine/ml every 5 days. For the
patient who experienced remission in UC, no nicotine concentration
was noted; however, he was taking an average of 105 puffs/day from
his EC. Themotherwhose infantwas bornwith necrotizing enterocolitis
used her EC approximately 30–50 times/day for a duration of less than
5 min/session, and, during the time of active labor she was using her
EC for approximately 50–70 times/day. It was also estimated that she
had taken in 0.8–1 mg of nicotine daily and this increased to 1–1.4 mg
before labor.
3.1.3. Cardiovascular system
The two cases involving the cardiovascular system were diagnosed
as paroxysmal atrial ﬁbrillation (PAF) and acute myocardial infarction
(Monroy et al., 2012; Kivrak et al., 2014). The patient who experienced
PAF was an elderly female who was a dual user of EC and conventional
cigarettes. She had a history of high blood pressure and was receiving
care at a nursing facility. The patient diagnosed with acute myocardial
infarction was a young previously healthy male (24 years old). Both
patients had usedEC that contained nicotine, and the previously healthy
male reported using reﬁll ﬂuid that contained 16mg of nicotine/ml. No
details on usage patterns or ﬂavors were provided for either patient.
For the elderly patient, a clear initiation for onset of symptoms was
not described, but for the individual who experienced acute myocardial
infarction, symptoms began during EC use. The patient who experienced
PAF developed asymptomatic acute episodes of atrial ﬁbrillation
with rapid ventricular response. The patient who experienced acute
myocardial infarction presented with chest pain.
The patient experiencing PAF was transferred to a cardiac catheteri-
zation laboratory andwas administeredmedication intravenously. Both
patients with cardiovascular effects associated with EC use had improved
symptoms after appropriate medical care and monitoring of their condi-
tions. The patient with PAF was advised to abstain from EC use and her
condition improved to normal. The young male who experienced acutemyocardial infarction also improved to normal after medical treatment
and was discharged.
3.1.4. Neurological system
One individual experienced reversible cerebral vasoconstriction
syndrome (RCVS) (Vannier et al., 2015). This patient had a smoking
history of 60 cigarettes/day for 20 years, but did not have a priormedical
history. The individual presented to an emergency room with a 7 day
history of headaches and two seizures. The patient was a dual user of
EC and conventional cigarettes. He began experiencing an onset of
headaches 2 days after starting EC use and smoking 20 cigarettes/day.
At days 3 and 4, the patient experienced severe thunderclap headaches.
The EC used by this individual had a nicotine concentration of 12mg/ml;
however, details were not provided on frequency of EC usage. The patient
receivedmedical care andwas advised to abstain fromECuse. The patient
continued to smoke 10–15 cigarettes/day, and his headaches resolved
after 3 days. A 1 month follow-up with MRI conﬁrmed RCVS with
resolving stenosis and overall improvement in his condition after stop-
ping EC use completely.
3.1.5. Immune system
One case reported a positive health effect associated with EC use for
a male patient with previous history of idiopathic neutrophilia
(Farsalinos and Romagna, 2013). This case report followed the patient
for 7 years (from 2005 to 2012) after his initial diagnosis. The patient
was a smokerwho previously attempted unsuccessful smoking cessation.
He had been treated for high cholesterol since 2003. In 2012, the patient
started using EC for smoking cessation and was successful within
10 days. After 6 months of EC use and smoking cessation, the patient
experienced a reversal of idiopathic neutrophilia at which time his condi-
tion returned to baseline/normal count.
3.1.6. Mechanical injury
Two cases of mechanical injury have been reported in the peer
reviewed literature (Jablow and Sexton, 2015; Rogér et al., 2016).
The ﬁrst involved an adult male who received severe right leg burns
as a result of a spontaneous explosion of his EC battery. An image of the
device was provided in the case report; however, no further details
concerning the EC brand, model or battery were available.
The second case involved an adult male who suffered oral injuries
when an EC he was using exploded in his mouth. The patient suffered
oral and abdominal burns, oral lacerations, tooth fractures, and tooth
avulsions. The patient received follow-up dental care to evaluate his
oral trauma. No further details were provided concerning the EC device
brand, model or battery.
3.1.7. Nicotine poisonings associated with EC use and routes of exposure
Eleven case reports for 12 individuals (4 children and 8 adults)
document nicotine poisonings. These reports describe both accidental
and intentional/suicide attempts associated with EC. Cases reporting
nicotine poisonings for both accidental and intentional/suicidal
attempts involved ﬁve different routes of administration including:
(1) ingestion of EC liquid nicotine (N = 11), (2) intravenous injection
(N = 2), (3) dermal exposure (N = 1), (4) use of EC with other drug
substances and/or additional sources of nicotine (N = 2), and
(5) combined routes of administration (such as ingestion and intravenous
injection to EC liquid nicotine) (N= 2).
3.1.8. Accidental nicotine poisonings associated with EC
Three cases of accidental nicotine poisonings associated with EC
involved children (Bassett et al., 2014; Gupta et al., 2014; Gill et al.,
2015). The children in the reports ingested liquid nicotinewhichwas re-
ported in two cases to be wintergreen and grape ﬂavored. These children
experienced varying effects fromnicotine poisoning thatwere eithermild
(two cases) or serious (one case). All children had symptoms of vomiting.
For mild cases, one child experienced vomiting after ingestion of EC reﬁll
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changes. In the one severe case of nicotine poisoning, the infant experi-
enced tachycardia, respiratory changes, and ataxia. In all cases the chil-
dren recovered from nicotine poisoning following medical treatment.
3.1.9. Intentional misuse/suicidal attempts associated with EC
Eight case reports involving nine individuals (8 adults and 1 adoles-
cent) are categorized as intentional or suicide attempts related to EC
(Cervellin et al., 2013; Christensen et al., 2013; Valento, 2013; Eberlein
et al., 2014; Schipper et al., 2014; Thornton et al., 2014; Bartschat
et al., 2015; Chen et al., 2015). One case reported accidental overdose
by intravenous injection of EC liquid combined with use of other recre-
ational drugs. Six other individuals attempted suicide by internalization
of EC liquid using varying routes of exposure. Nicotine concentrations in
reﬁll ﬂuids varied from 18 to 100 mg/ml.
Of eight attempted suicides, three deaths have been reported
(Thornton et al., 2014; Bartschat et al., 2015; Chen et al., 2015).
These cases reported that EC liquid nicotine was primarily ingested or
intravenously injected at above lethal doses (2000 ng/ml in Thornton
et al., 2014, 3950 mg in gastric contents, Bartschat et al., 2015, and
1000 ng/ml in Chen et al., 2015). Five of the eight individuals who
attempted suicide had a history ofmental illness, including the three indi-
viduals who died.
3.1.10. Nicotine usage reported in case reports
Nicotine concentrations were provided in six systemic and six
poisonings cases reports. For systematic events, the average nicotine
concentration in EC products was 14.4 mg/ml ± 3.9 with a range of
9–19 mg/ml. For nicotine poisonings, the average nicotine concentration
available to EC users was 29.1 mg/ml ± 19.4 with a range of 18–
100 mg/ml.
4. Discussion
The number of peer reviewed case reports dealing with EC is now
sufﬁciently large to provide insight into the negative and positive health
effects that EC can have. The types of health effects attributed to EC are
summarized in Fig. 2. Most case reports involved system effects andFig. 2. Summary of all case reporpoisonings. System effects were diverse and some involved an immune
response including inﬂammation that occurred in the respiratory and
gastrointestinal systems (McCauley et al., 2012; Hureaux et al., 2014;
Thota and Latham, 2014; Moore et al., 2015; Atkins and Drescher,
2015; Modi et al., 2015; Camus et al., 2014; Gillen and Saltzman,
2014; Thota and Latham, 2014). The systems with most reports were
respiratory (N = 6), gastrointestinal (N = 3), and cardiovascular
(N= 2), which is in agreement with our prior infodemiological report
dealing with adverse health effects reported by EC users in online
forums (Hua et al., 2013). Certain conditions associated with EC use,
such as acute myocardial infarction in a previously healthy young
male, RCVS, and necrotizing enterocolitis, are medically uncommon. In
addition to the two peer-reviewed cases of lipoid pneumonia associated
with EC usage, two news outlets reported separate cases in Spain and
the UK (The Local, 2014; The Journal, 2011). One patient developed
lipoid pneumonia after he continuously used an EC while recovering
in a hospital in Spain, and another report links the death of a UK man
to lipoid pneumonia with EC usage.
While there were 12 peer-reviewed case reports linking nicotine
poisonings to ECproducts, the actual number of suchpoisonings is rapidly
increasing according to Poison Control Center reports and exceeded 3000
in 2014 (Chatham-Stephens et al., 2014). The potential for accidental
poisoning is increased by readily available EC products with high concen-
trations of nicotine, ﬂavors that are attractive to children, and the lack of
accurate labeling on some EC products that contain nicotine (Trehy
et al., 2011; Davis et al., 2015a,b). Poisoning of children could be reduced
by child-prooﬁng EC reﬁll ﬂuid products, which is already done by some
manufacturers and will be required of all EC products containing nico-
tine once the Child Nicotine Poisoning Prevention Act goes into effect
(Civic Impulse, 2016).
In addition to the three deaths in Table 1, seven deaths have been
linked to EC products in the FDA-CTP database (Durmowicz, 2014) and
major news outlets. These include adults and young children from the
US, UK, Europe and Israel (Mohney, 2014; BBC, 2014; Kloosterman,
2013; The Journal, 2011; Linning, 2015; The DailyMail, 2015). Four adults
died from nicotine poisoning due to suicide in the US and Europe (BBC,
2014; Thornton et al., 2014; Bartschat et al., 2015; DailyMail, 2015); one
man from the UK died from EC mechanical injury due to an explosionts and categories of effects.
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temic effects attributed to lipoid pneumonia in the UK (The Journal,
2011). Two children from the US (Mohney, 2014) and one child from
Israel died (Kloosterman, 2013) due to nicotine poisoning from ingestion
of EC reﬁll ﬂuids or choking on an EC ﬂavor cartridge (Durmowicz, 2014).
Additionally, EC products and reﬁll ﬂuids provide a new readily accessible
source of nicotine that can be used for intentional poisoning.
Although the case reports do not identify speciﬁc chemicals causing
health outcomes, the reported systemic effects (e.g. infantile necrotizing
colitis, RCVS, ulcerative colitis, atrial ﬁbrillation, acute myocardial
infarction) could be caused bynicotine,whichhas been linked to gastro-
intestinal, neurological, and vascular disorders (Naik and Cucullo, 2015;
Mishra et al., 2015). For instance, nicotine could trigger atrial ﬁbrillation
and other abnormal cardiovascular events, such as the acutemyocardial
infarction in a previously healthyman (Kivrak et al., 2014). Additionally,
nicotine has potential vasoconstrictive effects on the brain and can
induce inﬂammation in the lungs that imitates metastatic cancer
(Naik and Cucullo, 2015; Mishra et al., 2015; Madsen et al., 2016). EC
aerosols are also rich in propylene glycol and glycerin. Although these
are usually considered non-toxic (ATDSR, 2011), the amounts being
inhaled by EC users are large and may be of concern (Behar et al., 2015;
Burstyn, 2014). Propylene glycol can cause allergic and inﬂammatory
reactions and irritate the lungs, skin and eyes (Choi et al., 2011), and all
of the respiratory diagnoses included inﬂammation. Persistent lung
inﬂammation caused by EC aerosols could lead to lung pathogenesis
and trigger serious diseases such as chronic obstructive pulmonary
disease and ﬁbrosis (Rowell and Tarran, 2015).
The reports concerning relapsed and improved UC are the ﬁrst case
reports linking EC use to these conditions (Lee et al., 2013; Camus et al.,
2014; Gillen and Saltzman, 2014). For patients with UC, smoking conven-
tional cigarettes can have beneﬁcial and protective effects (Thomas et al.,
1998; Calkins, 1989). The cases with opposite effects in EC users suggest
that there are factors other than nicotine consumption that work to
improve or aggravate conditions in patients with preexisting conditions.
It is also important that ECs vary considerably in their performance and
contents (Trtchounian et al., 2010; Williams and Talbot, 2011; Williams
et al., 2013, 2014, 2016) and opposite effects, as reported with UC, could
be related to the speciﬁc products used by the patients and the efﬁciency
of their delivery. In addition, topography differs signiﬁcantly among EC
users (Behar et al., 2015). Thismay also affect nicotine and propylene gly-
col delivery, depth of penetration of aerosol into the lungs, and total
amount of aerosol exposure, all of which may inﬂuence health outcomes
(Behar et al., 2014a,b). Individual EC usage (product and liquid nicotine),
smoking history, and pre-existing health history need to be monitored
and considered carefully to better understand the opposing effects of
ECs on users with a history of UC.
While EC are sometimes recommended by physicians to pregnant
women as a less harmful alternative than tobacco cigarettes and are
perceived as safe to use during pregnancy by pregnant women (Mark
et al., 2015; Kahr et al., 2015), our data suggest that pregnant women
should approach EC use with caution and be informed of the potential
complications that may affect their pregnancy. This idea is further sup-
ported by in vitro toxicity studies that have reported that embryonic
cells are more sensitive to EC reﬁll ﬂuids than differentiated adult cells
of the lungs (Bahl et al., 2012). Additionally, studies have shown that EC
exert negative prenatal and postnatal effects on lung growth and adult
behavior of mice (McGrath-Morrow et al., 2015; Smith et al., 2015).
The two case reports dealing with mechanical injury resulted from
spontaneous explosion of the EC battery. Such accidents can be triggered
by modiﬁcation of the EC, overheating, or using an incorrect battery
charger (USFA, 2014). EC explosions can result in ﬁres, explosions, severe
injuries, burns, and death (BBC, 2014; USFA, 2014; Durmowicz, 2014).
Most explosion related injuries have not appeared in the peer reviewed
literature, but a recent report by the 2014US Fire Administration concise-
ly documents many incidents of exploding EC that have caused injury to
users (USFA, 2014). Numerous reports of explosions have appeared inprint andnewsmedia and lawsuits have beenﬁled to compensate victims
of such explosions (LA Times, 2015). The Department of Transportation
recently prohibited storage of EC in checked baggage on airplanes
to avoid damage and injury due to an explosion (Department of
Transportation, 2015).
In summary, EC have their own set of health effects that need to be
better characterized and understood. Data from case reports show that
EC use can be accompanied by negative and, less frequently, positive
health effects. Health was affected by EC use in both adults and children
(non-users), as well as adults without pre-existing conditions, adults
with mental illness, and a newborn exposed during pregnancy. For
nicotine poisonings and injuries due to EC explosion, the number of
case reports and range of negative effects are not representative of actual
incidents. Many additional reports have appeared in print media and on
government andmedical websites that collect health data. It is also likely
that the systemic effects caused by EC are currently under-reported in
peer-reviewed literature. Although most individuals who experienced
negative health effects eventually recovered, their risk for recurrence is
an important issue for health care professionals to consider.
Finally, a consistent and uniform presentation of data in future case
reports dealingwith EC is needed. Alongwith patient demographics and
smoking history, previous health history, and positive and negative
diagnoses, it would be helpful if case reports included details pertaining
to: (1) the frequency of EC use; (2) EC nicotine concentration, brands,
and ﬂavors; (3) the time of onset of symptoms after EC use; (4) the
conditions that are linked to EC; (5) if symptoms reversed after cessation
of EC; and (6) follow-up reports on patients.
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